null

null

null

null

null

null

null

null

null

Minimal debt; primarily equity-financed with ~$1.8B cash runway; negligible leverage ratio; 20% rate rise has near-zero P&L impact

Low sensitivity; no significant floating-rate debt; higher rates modestly reduce treasury income on cash reserves (~$1.8B)

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Chinese API/reagent suppliers for RAS inhibitor synthesis; 2) Single-source CDMOs concentrated in U.S./EU with limited geopolitical redundancy

Minimal international revenue currently; pre-commercial stage; sovereign currency devaluation exposure is negligible at this time

Primarily U.S.-based operations and clinical trials; limited ex-U.S. revenue exposure; EU/APAC trial sites add minor FX risk

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on select CDMOs (e.g., WuXi AppTec network) for drug substance manufacturing; likely exceeds 30% of COGS input

Clinical-stage biopharmaceutical; R&D-driven with collaboration revenue; cloud disruption would impair data systems but not core drug IP

Milestone and royalty collaboration model (e.g., Sanofi partnership); secondary revenue from licensing agreements

Moderate API coupling risk; reliance on proprietary RAS biology platforms and CDMO relationships creates meaningful switching friction

Low Howey risk; revenue model is pharmaceutical licensing/milestones, not investment contracts; equity is standard registered securities

Very High

Moderate GDPR/CCPA exposure from clinical trial patient data across EU/U.S. sites; standard pharma compliance protocols apply

Low current antitrust risk; pre-commercial, no dominant market share; future RAS inhibitor monopoly pricing could draw scrutiny post-approval

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~100% transactional/milestone-based collaboration revenue; no recurring subscription revenue; Sanofi deal provides structured milestone payments

Upfront payments, R&D milestones, and future royalties on net sales from Sanofi collaboration; potential product sales post-approval

Drug pricing TBD pre-commercialization; oncology peer benchmarks suggest $15K–$25K/month WAC; pricing power tied to unmet need in RAS-driven cancers

High potential pricing power; first/best-in-class KRAS/RAS(ON) inhibitors in oncology command premium; limited substitutes currently

Projected 75–85% gross margin at commercial scale, consistent with targeted oncology small-molecule drug benchmarks

No free-rider problem; drug IP is proprietary; clinical/commercial access requires prescription and reimbursement; minimal leakage risk

Sublinear growth expected post-approval; R&D headcount-intensive now, but commercial scale leverages existing platform; partnership reduces field force need

Marginal cost of revenue growth is low post-approval given Sanofi co-commercialization; incremental R&D costs are high per pipeline asset

Not applicable; not a franchise business model

At 10x scale, oncologist adoption and payer coverage become key CAC drivers; estimated CAC in specialty pharma ranges $50K–$200K per physician account

Weak direct network effects; indirect effects possible via real-world data accumulation improving biomarker selection and label expansion

-48.0% Return on Assets (Negative equity)

High recession resistance; oncology treatments are non-discretionary; demand largely inelastic to economic cycles

Oncologists and cancer centers treating RAS-mutant solid tumors (KRAS G12C and broader RAS(ON) patient populations)

Large pharma partners (Sanofi) as collaboration customers; payers/PBMs as access gatekeepers for future commercial products

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital primarily allocated to R&D pipeline advancement; minimal legacy infrastructure; investment concentrated in future-state clinical and manufacturing capabilities

0001628171

RVMD